FAQ on Clene Inc.'s Corporate Update at the Emerging Growth Conference

What is Clene Inc. presenting at the Emerging Growth Conference?

Clene Inc. will deliver a virtual corporate update, including details on its lead therapeutic candidate CNM-Au8, at the Emerging Growth Conference on April 17, 2025.

When and where will the Clene Inc. presentation take place?

The presentation is scheduled for April 17, 2025, at 12:00 p.m. EDT, and will be webcast on Clene’s website and through the conference portal.

Who can attend the Clene Inc. presentation at the Emerging Growth Conference?

The presentation is virtual and open to anyone interested, with access available via Clene’s website and the conference portal.

What is CNM-Au8 and what diseases does it target?

CNM-Au8 is an investigational therapy by Clene Inc. aimed at improving mitochondrial health and neuronal function to treat neurodegenerative diseases like ALS, Parkinson’s disease, and multiple sclerosis.

Will there be a replay of the Clene Inc. presentation available?

Yes, a replay of the presentation will be available following the event on Clene’s website and possibly through the conference portal.

How can I get more information about Clene Inc.?

For more information about Clene Inc., visit their website at www.Clene.com or check the latest news and updates in the company’s newsroom at https://ibn.fm/CLNN.

What is the significance of Clene Inc.’s presentation at the Emerging Growth Conference?

The presentation is significant as it provides updates on Clene Inc.’s clinical-stage developments, particularly CNM-Au8, offering insights into potential treatments for neurodegenerative diseases.

Where is Clene Inc. based and where are its operations located?

Clene Inc. is based in Salt Lake City, Utah, with research and development (R&D) and manufacturing operations in Maryland.